Parsonage-Turner syndrome (PTS) is a rare brachial plexus neuropathy that typically presents as a severe, sudden-onset pain followed by atrophic weakness with slow recovery, which may occur after an identifiable triggering event. Vaccination is one of several known triggers of PTS, and this syndrome has already been reported in other patients who were vaccinated against coronavirus disease.We report the case of a 75-year-old Caucasian man who received the third dose of the coronavirus disease 2019 (COVID-19) Oxford/AstraZeneca vaccine and was diagnosed with PTS. A week after inoculation, the patient, with no history of trauma, developed a sudden-onset left shoulder mechanical pain and later reported an abduction deficit. Neurological examination showed an atrophy of the proximal muscles of the left upper limb. No bulbar weakness or pathological upper motor neuron signs were seen. The MRI excluded rotator cuff pathology, including ruptures and tendinopathy. Electroneuromyography findings carried out 10 months after the onset of symptoms indicated left brachial panplexopathy, suggestive of PTS.The raised consciousness of PTS and vaccine association is crucial for prompt identification and diagnosis and, therefore, better clinical outcomes.
Purpose: Functional capacity (FC) declining has been poorly evaluated and characterized in women with breast cancer (BC). It is expected that FC declining may have an impact on survival, and also compromise quality of life and independence. This study aimed to evaluate the FC of women with BC and identify predictors of obtained results. Methods: A cross-sectional study including women with BC consecutively referred for a physical medicine and rehabilitation consult between October and December 2019. Glittre-ADL Test (TGlittre), maximal respiratory pressure tests [maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)] and Modified Fatigue Impact Scale were used in order to assess FC, respiratory muscle strength and fatigue, respectively. Age, professional status, smoking habits, comorbidities, body mass index, duration and status of disease, previous and ongoing treatments were also registered. Results: A total of 42 women with non-metastatic BC were enrolled with a disease duration of 11.50 months (71), mostly in stage II (53.60%) and under hormone therapy (38.10%). TGlittre performance time was 3.13 minutes (8.72). TGlittre performance time correlated with MIP (r = -0.373; p <0.01) and MEP (r = -0.414; p = 0.007) values and age (r = 0.711; p < 0.010). Patients with CV and endocrine comorbidities had higher TGlittre time values (p <0.01 and p = 0.019, respectively). Age was the only statistically significant predictor (p=0.041) of TGlittre variation.Conclusions: Women with BC presented decreased FC with mean values of TGlittre duration higher than those described in the literature in healthy subjects.
A number of options are currently available to treat symptomatic knee and hip pain. Among them, there is the use of thermal radiofrequency ablation. It is a more recent technique and we still have a lack regarding safety and effectiveness. In this report, we briefly present a case series of patients with refractory knee and hip pain, treated with thermal radiofrequency ablation, where we discuss the results in safety and effectiveness, concerning not only the pain control, but also the return to participation in activities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.